BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 21508387)

  • 1. Effect of tamoxifen or anastrozole on steroid sulfatase activity and serum androgen concentrations in postmenopausal women with breast cancer.
    Stanway SJ; Palmieri C; Stanczyk FZ; Folkerd EJ; Dowsett M; Ward R; Coombes RC; Reed MJ; Purohit A
    Anticancer Res; 2011 Apr; 31(4):1367-72. PubMed ID: 21508387
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I study of STX 64 (667 Coumate) in breast cancer patients: the first study of a steroid sulfatase inhibitor.
    Stanway SJ; Purohit A; Woo LW; Sufi S; Vigushin D; Ward R; Wilson RH; Stanczyk FZ; Dobbs N; Kulinskaya E; Elliott M; Potter BV; Reed MJ; Coombes RC
    Clin Cancer Res; 2006 Mar; 12(5):1585-92. PubMed ID: 16533785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Steroid sulfatase: a new target for the endocrine therapy of breast cancer.
    Stanway SJ; Delavault P; Purohit A; Woo LW; Thurieau C; Potter BV; Reed MJ
    Oncologist; 2007 Apr; 12(4):370-4. PubMed ID: 17470679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of steroid sulfatase in local formation of estrogen in post-menopausal breast cancer patients.
    Nakata T; Takashima S; Shiotsu Y; Murakata C; Ishida H; Akinaga S; Li PK; Sasano H; Suzuki T; Saeki T
    J Steroid Biochem Mol Biol; 2003 Sep; 86(3-5):455-60. PubMed ID: 14623544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anastrozole ('Arimidex') blocks oestrogen synthesis both peripherally and within the breast in postmenopausal women with large operable breast cancer.
    Miller WR; Stuart M; Sahmoud T; Dixon JM
    Br J Cancer; 2002 Oct; 87(9):950-5. PubMed ID: 12434282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of aromatase inhibitors in breast carcinoma.
    Santen RJ; Harvey HA
    Endocr Relat Cancer; 1999 Mar; 6(1):75-92. PubMed ID: 10732791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of exemestane, anastrozole, and tamoxifen on lipid profiles in Japanese postmenopausal early breast cancer patients: final results of National Surgical Adjuvant Study BC 04, the TEAM Japan sub-study.
    Hozumi Y; Suemasu K; Takei H; Aihara T; Takehara M; Saito T; Ohsumi S; Masuda N; Ohashi Y
    Ann Oncol; 2011 Aug; 22(8):1777-82. PubMed ID: 21285133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-tumor effects of letrozole.
    Miller WR; Anderson TJ; Dixon JM
    Cancer Invest; 2002; 20 Suppl 2():15-21. PubMed ID: 12442345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suppression of plasma estrogen levels by letrozole and anastrozole is related to body mass index in patients with breast cancer.
    Folkerd EJ; Dixon JM; Renshaw L; A'Hern RP; Dowsett M
    J Clin Oncol; 2012 Aug; 30(24):2977-80. PubMed ID: 22802308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of aromatase inhibitors in the treatment of metastatic breast cancer.
    Mouridsen H; Gershanovich M
    Semin Oncol; 2003 Aug; 30(4 Suppl 14):33-45. PubMed ID: 14513435
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Focus on anastrozole and breast cancer.
    Mokbel K
    Curr Med Res Opin; 2003; 19(8):683-8. PubMed ID: 14687437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new therapeutic strategy against hormone-dependent breast cancer: the preclinical development of a dual aromatase and sulfatase inhibitor.
    Foster PA; Chander SK; Newman SP; Woo LW; Sutcliffe OB; Bubert C; Zhou D; Chen S; Potter BV; Reed MJ; Purohit A
    Clin Cancer Res; 2008 Oct; 14(20):6469-77. PubMed ID: 18927286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anastrozole: a review of its use in postmenopausal women with early-stage breast cancer.
    Sanford M; Plosker GL
    Drugs; 2008; 68(9):1319-40. PubMed ID: 18547136
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.
    Margolese RG; Cecchini RS; Julian TB; Ganz PA; Costantino JP; Vallow LA; Albain KS; Whitworth PW; Cianfrocca ME; Brufsky AM; Gross HM; Soori GS; Hopkins JO; Fehrenbacher L; Sturtz K; Wozniak TF; Seay TE; Mamounas EP; Wolmark N
    Lancet; 2016 Feb; 387(10021):849-56. PubMed ID: 26686957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New development in intracrinology of breast carcinoma.
    Sasano H; Suzuki T; Nakata T; Moriya T
    Breast Cancer; 2006; 13(2):129-36. PubMed ID: 16755106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial.
    Sestak I; Distler W; Forbes JF; Dowsett M; Howell A; Cuzick J
    J Clin Oncol; 2010 Jul; 28(21):3411-5. PubMed ID: 20547990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anastrozole versus tamoxifen as first-line therapy in postmenopausal patients with hormone-dependent advanced breast cancer: a prospective, randomized, phase III study.
    Milla-Santos A; Milla L; Portella J; Rallo L; Pons M; Rodes E; Casanovas J; Puig-Gali M
    Am J Clin Oncol; 2003 Jun; 26(3):317-22. PubMed ID: 12796608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anastrozole ('Arimidex') versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: results of the double-blind cross-over SAKK trial 21/95--a sub-study of the TARGET (Tamoxifen or 'Arimidex' Randomized Group Efficacy and Tolerability) trial.
    Thürlimann B; Hess D; Köberle D; Senn I; Ballabeni P; Pagani O; Perey L; Aebi S; Rochlitz C; Goldhirsch A
    Breast Cancer Res Treat; 2004 Jun; 85(3):247-54. PubMed ID: 15111763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial.
    Goss PE; Hershman DL; Cheung AM; Ingle JN; Khosla S; Stearns V; Chalchal H; Rowland K; Muss HB; Linden HM; Scher J; Pritchard KI; Elliott CR; Badovinac-Crnjevic T; St Louis J; Chapman JA; Shepherd LE
    Lancet Oncol; 2014 Apr; 15(4):474-82. PubMed ID: 24636210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Three years' follow-up from the ATAC trial is sufficient to change clinical practice: a debate.
    Aapro MS; Forbes JF
    Breast Cancer Res Treat; 2003; 80 Suppl 1():S3-11; discussion S13-8. PubMed ID: 14535530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.